PRUDENTIAL FINANCIAL INC (PRU): what the price requires

At today's price, PRUDENTIAL FINANCIAL INC (PRU) is priced for 12.2% return on equity. boothcheck doesn't publish a fair value or a price target; it shows what the price assumes, so you can judge whether that bar is too high.

Generated: 2026-07-14 · Exported: 2026-07-16 · Source: https://boothcheck.com/report/PRU

Headline

FieldValue
TickerPRU
CompanyPRUDENTIAL FINANCIAL INC
Current price$116.16/sh
CompositionPGIM 11% / Retirement Strategies 56% / Group Insurance 17% / Individual Life 16%

What The Price Requires (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

FieldValue
Inversion basisfinancials
Return on equity needed12.2%
Return on equity now11.0%
ROE gap+1.2pp
Price-to-book1.26x

Solve inputs: computed at a 10.5% cost of equity with 4% terminal growth over a 5-year stage, on common book equity (FY2026); each 1pp of cost of equity moves the implied ROE ~1.3pp.

Reconcile: at the x-ray's 9.3% required return this reads ~10.6%; the models below use their own rates.

How unusual the bet is: within-range

ReferenceValue
vs own history+0.82σ
cohort percentile (of 80 peers)25
sustained it ~10 years at this level69%
implied end-window share0%

Valuation X-Ray

The price is supported by asset-based and earnings-power and relative-multiple and growth-DCF value. A value/asset-supported name, not a pure growth bet.

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

FamilyMedian price/FVModelsReads
Asset1.00x3justifies
Earnings0.74x2justifies
Relative1.00x3justifies
Growth0.92x2justifies

Families that justify the price: Asset, Earnings, Relative, Growth

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 7.5%); the inversion above states its own rate.

Per-Model Detail (n=10)

ModelFamilyFVPrice/FVApplicableMethodology
DCF Perpetual GrowthGrowth——no—
Bank Fair Value (P/TBV)—$108.421.07xyesTBVPS $91.51 × 1.18x (ROE (TTM) 10.8% / CoE 9.3%, g=5.0% (sustainable: 65% retention × ROE, 5% cap; not the terminal-growth assumption), credit 0.74% allowance/loans → ×0.90, NPL 1.54% → ×0.96)
Relative ValuationRelative$115.831.00xyesP/E 11x (static sector reference · 2026-04), scenarios: 9.2x / 11.0x / 12.8x (bear / base = reference held flat / bull), EV/EBITDA 22x
Simple DDMGrowth——no—
Two-Stage DDMGrowth$203.810.57xyesStage 1: 20% for 5yr, Stage 2: 3.5% perpetual
Simple Excess ReturnAsset$107.241.08xyesBV/sh $91.51, ROE (TTM) 10.8%, ke 9.3%
Two-Stage Excess ReturnAsset$115.751.00xyes5yr excess ROE then converge to ke=9.3%
Discounted Future Market CapGrowth$91.321.27xyesRev $62.8B, growth 6% (input: historical growth; tapered), Terminal P/S: 0.5x / 0.6x / 0.7x (bear / base = today's held flat / bull, cap 8x)
Peter Lynch Fair ValueRelative$116.521.00xyesEPS $9.71, growth 2% (input: historical EPS growth), PEG=5.86 (Overvalued)
Margin TrajectoryGrowth——no—
Earnings Power ValueEarnings——no—
Residual IncomeAsset——no—
Graham NumberAsset$141.400.82xyes√(22.5 × EPS $9.71 × BVPS $91.51) — Graham's conservative floor
EV/EBITDA RelativeRelative——no—
FCF YieldEarnings——no—
SBC-Adj FCF YieldEarnings——no—
Ben Graham FormulaEarnings$313.310.37xyesEPS $9.71 × (8.5 + 2×15.0%) × (4.4 / 5.3%)
ROIC-Justified P/BAsset——no—
P/Sales SectorRelative——no—
PEG Fair ValueRelative$364.130.32xyesEPS $9.71 × (PEG 1.5 × growth 25.0% (input: historical EPS growth)) → PE 37.5x
Earnings YieldEarnings$104.971.11xyesEPS $9.71 / required return 9.3% (Rf 4.3% + ERP 5.0%)
Funds From Operations MultipleRelative——no—
Clinical Phase NPVGrowth——no—
MertonAsset——no—
V5 Mechanical———no—

Solvency

FieldValue
Share count CAGR (buyback)-1.8%

Deposit/float-funded balance sheet: debt is funding, not corporate leverage, and GAAP operating cash flow follows loan flows. Net-debt, interest-coverage, and cash-burn lenses do not apply. The solvency frame for a financial is regulatory capital and payout capacity (CET1, stress buffer, dividends plus buybacks against earnings).

Bullet Takeaways

Bull Case

The most useful way to read Prudential is to see where the price sits against the valuation methods, because for once it sits below most of them. An insurer is worth the return it earns on its capital, so the right lens is price-to-book, and at about $107 (June 27, 2026) the stock trades near 1.2 times book while implying a sustained return on equity of roughly 11.5%. It has recently earned about 11%. That is a small ask, and it explains why the asset, earnings-power, peer-multiple, and growth frames all support the current price rather than stretching for it. The spread across methods says the market is not paying up for Prudential; it is pricing a steady, capital-backed franchise at a modest premium to its book.

The earnings engine behind that book is diversified and increasingly fee-led. Retirement Strategies is the largest piece of the business at roughly 56% of the mix, with PGIM, Group Insurance, and Individual Life rounding it out. PGIM is the asset-management arm, and it carried the first quarter, with adjusted operating income up 22% year over year and assets under management of $1.433 trillion. The 10-K lays out the competitive landscape Prudential operates in across "Institutional Retirement Strategies" where it competes "with other large" providers (FY2025 10-K, accession 0001137774-26-000048), a market where scale, ratings, and distribution are the moat. A balance-sheet business with a large fee overlay is more durable than a pure spread lender.

The capital story is what a value buyer is really paying for. In the first quarter Prudential returned $746 million to shareholders, $250 million in buybacks and $496 million in dividends of $1.40 per share, while still generating after-tax adjusted operating income of $1.278 billion and beating estimates by a wide margin. The share count has been shrinking at roughly 2% a year. For a stock trading near book with a covered dividend and a buyback that compounds per-share value, the bar to a reasonable outcome is low: it does not need multiple expansion or heroic growth, only for the franchise to keep earning roughly what it already earns.

Bear Case

The disruption that matters for Prudential right now is not a competitor; it is a self-inflicted wound in Japan, and it is the place to start. The company's Japanese life arm has voluntarily suspended new sales after disclosing that roughly 100 current and former employees improperly took funds from customers. What began as a 90-day pause has been extended by another 180 days, pushing the freeze into November 2026, and management said the required fixes to operations, governance, and organizational structure are broader than first expected. The financial consequence is concrete: management withdrew its growth target and guided to a pretax adjusted operating income hit of roughly $525 million to $575 million in 2026 and a further $400 million to $450 million in 2027. Japan, run through the Gibraltar Life and Life Planner segments the 10-K describes as core to "International Businesses" (FY2025 10-K, accession 0001137774-26-000048), has been a profit anchor, and Japan's Financial Services Agency has opened an on-site inspection that could bring business improvement orders.

Beneath the headline, the competitive setting is genuinely hard. In retirement and annuities, Prudential competes "with other large" institutional players (FY2025 10-K, accession 0001137774-26-000048), a field crowded with well-capitalized insurers and, increasingly, private-capital-backed annuity platforms that are repricing the cost of liabilities. PGIM is strong but operates in asset management, where fee compression and passive competition are structural headwinds even when assets rise with the market. None of these businesses is growing fast; they grow with markets and with capital deployed, which is why the implied return on equity, not a growth rate, is the variable that matters.

The valuation gives little reward for taking that risk. Analyst sentiment reflects the caution, with several firms holding underweight ratings and trimming targets on regulatory and Japan concerns. If the Japan remediation drags, if surrenders accelerate while sales are frozen, or if the FSA inspection escalates, the earnings power that justifies the current book multiple comes under pressure, and a stock priced for steadiness does not have a discount to fall back on.

Valuation

Prudential is valued the way an insurer should be, off price-to-book rather than an operating multiple, because its worth is the return it earns on its capital. At about $107 the stock trades near 1.16 times book and implies a sustained return on equity of roughly 11.5%, computed at a 10.5% cost of equity with 4% terminal growth over a five-year stage. It has recently earned about 11%, so the assumed return is within reach of its own record, and the inversion reads the overall priced-in level as within range rather than elevated.

What stands out is that every family supports the price. The asset frame, the earnings-power frame, the peer-multiple frame, and the growth-DCF all land at or just below the current quote, which is the signature of a value and asset-backed name rather than an expectations stock. The reasonable-return band built from the inversion runs from a low near $66 to a base around $82 and a high near $126, a wide range that reflects how sensitive an insurer's value is to the return-on-equity assumption: each point of cost of equity moves the implied return by a bit over a point. Against peers, the price-to-book sits in the lower half of the group, so Prudential is not the expensive insurer.

The honest framing is that this is a modest premium to book for a diversified franchise that earns its cost of capital, returns most of its earnings to shareholders, and is shrinking the share count. The thing the valuation does not fully price is the Japan disruption, which is a near-term earnings drag of known but uncertain size. A buyer at this level is underwriting that the franchise keeps earning roughly 11% once Japan normalizes, and accepting that there is no cheap-multiple cushion if it does not.

Catalysts

The dominant catalyst is the Japan sales suspension and its resolution. The freeze, prompted by disclosed employee misconduct, has been extended into November 2026, and Japan's Financial Services Agency has begun an on-site inspection. Management has quantified the drag at roughly $525 million to $575 million of pretax adjusted operating income in 2026 and $400 million to $450 million in 2027, and has withdrawn its prior growth target. Any update on the inspection, the remediation timeline, or the pace of surrenders while sales are paused will move the stock, and a clean restart on schedule would remove a meaningful overhang.

The ongoing results tell a steadier story. First-quarter 2026 after-tax adjusted operating income was $1.278 billion, or $3.61 per share, up from $3.29 a year earlier and ahead of estimates, with PGIM operating income up 22% and assets under management of $1.433 trillion. The next earnings reports are the checkpoints for whether the rest of the franchise can offset the Japan hit. Capital return is a continuing support: the company paid a $1.40 quarterly dividend and bought back stock, and the cadence of buybacks and any dividend action are catalysts in their own right for a value holder.

The risks beyond Japan are the familiar ones for a large insurer. Interest-rate moves affect spread income and the value of the investment portfolio, equity markets drive PGIM fees and variable-annuity reserves, and credit conditions matter for the asset book. Analyst sentiment is cautious, with several firms at underweight and trimming targets, so a downgrade or a soft quarter could weigh on the shares even as the long-run capital-return case stays intact.

Peer Cohorts (Per Segment, With Filing Citations)

PGIM (reported)

Retirement Strategies (reported)

Group Insurance (reported)

Individual Life (reported)

International Businesses (reported)

Methodology Note

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.

View the full interactive PRU report on boothcheck